alzheimer disease

Alzheimer disease is the leading cause of dementia, affecting an estimated 55 million people globally and projected to triple by 2050. Amyloid and tau pathology remain the central therapeutic targets, with anti-amyloid monoclonal antibodies having reached regulatory approval in recent years. Disease-modifying therapy development is the most active area of clinical research in neurology.